Healthy, wealthy and wise by Cauchi, Maurice N.
health economIcs
this trio of desiderata is no less valid today than when we were children, but the recipe for success, summarised as ‘early to bed, early to rise’, appears to be too simplistic in a 
complex world we live in today.
And yet, if you ask a hundred people, particularly those of 
a certain age, when they have started to realise that they are not 
indestructible any more, what is the most valuable thing in life, 
the majority would choose health as the most urgent priority.
Compared to most countries in the world, Malta is a healthy 
nation. We are also a happy-go-lucky nation where it seems that 
some things go reasonably well more through luck than through 
wise management.
Surveys have shown that Maltese consider themselves some 
of the happiest in the world. In a scale that ranked happiness in 
countries around the world, Malta is listed as the 30th out of 157 
countries, beating countries like France, Italy, Cyprus, Japan, etc.1 
This index was built up from different components, namely: GDP 
per capita, social support, healthy life expectancy, freedom to 
make life choices, degree of generosity, perception of corruption, 
etc. So this is not just a subjective judgement of happiness, but is 
based on a number of socially-related factors. One factor which 
was not emphasized in this report is the efficiency of the health 
profession in producing this very acceptable state of affairs.
A more subjective Gallup survey consisted of interviews with 
people in 155 countries to obtain a ‘life evaluation’ score which 
varied on a scale from 1 to 10. Questions were asked relating 
to their experiences on the day previous to the interview and 
enquired about whether they felt well-rested, respected, free of 
pain, and intellectually challenged. On this scale also, subjective 
as it is, Malta ranked in the top quarter (at 38th position).2 
One important issue that comes out of the above study is 
that while 40% of Maltese were considered as ‘thriving’, nearly 
half of the population were classed as ‘struggling’, and 12% as 
actually ‘suffering’. 
Looking at any collection of data around the world, 
it becomes obvious that poor nations are also unhealthy 
nations. Not only are infectious diseases still the scourge of 
these nations, their short life is a constant battle for survival. 
The most obvious manifestation of poverty can now be 
seen as an explosion of people making the hazardous, often 
fatal rush to leave their country of origin and seek a home 
elsewhere, where the standard of living is higher and the 
future appears brighter.
Compared to the post-war period, when poverty was rife 
and the Maltese also had to leave these shores for pressing 
economic reasons, Malta has made gigantic economic progress. 
The standard of living is generally very good. The average salary 
has soared, from just over 10,000 euro in 2001 to over 17,000 
euro in 2016,3 a staggering 4% p.a.
In a recent publication The Health Gap4, Sir Michael 
Marmot, former President of the British Medical Association, 
emphasized the point that while poverty and ill-health are 
causally related, there is, however, a level of wealth above which 
additional increments are unlikely to have a significant effect. 
He analysed the effect of income on life expectancy, and while 
confirming that those countries with the lowest incomes also 
have the lowest life-expectancies, he concluded that “above 
a national income of $10,000, there is little relation between 
income and life expectancy”. In fact, he points out, that while 
the income is widely different in US compared to Cuba, there is 
little difference in life expectancy in US and Cuba. It would seem 
then that Malta, having now exceeded this critical wage level, is 
unlikely to witness a further increase in life expectancy through 
an increase in salaries.
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Reduces the potential 
for bacterial resistance
 Keratolytic2
 Treats comedones2 
and inﬂ ammatory 
lesions5
 Bactericidal action 
against P. acnes 
strains2
Benzoyl Peroxide Clindamycin
 Duac works fast, starting to work in just 2 weeks3 
 Duac is a once daily treatment2 






 Duac Once Daily Gel is indicated for the topical treatment of mild to moderate acne vulgaris, 
particularly inﬂ ammatory lesions in adults and adolescents from 12 years of age and above2
 Formulation contains added moisturisers, glycerin and dimethicone, for better tolerability1
YOUR EXPERT ADVICE CAN SHOW ON THEIR FACE
Duac comes ready-mixed, and is easy for your patients to use. It is recommended that you off er the following guidance4:
Once-daily, in the evening, your patients should2:
  Thoroughly wash the 
aff ected area of skin
  Gently pat dry   Apply a thin layer of Duac 
gel on the aff ected area, 
not just the individual spots
TIPS4
If your patient’s skin peels or becomes dry, they can try:
  Using an oil and fragrance-free hypoallergenic moisturiser
  Using Duac less often, or stopping for one or two days before 
starting again
Most common side eff ects include erythema, peeling, dryness, burning sensation, photosensitivity and headache
Duac® Once Daily 10mg/g + 50mg/g Gel Abridged Prescribing Information
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Trade Name: DUAC® ONCE DAILY GEL. Active Ingredients: Clindamycin phosphate/ anhydrous 
benzoyl peroxide. Pharmaceutical Form: 10mg/g + 50mg/g gel. Indication: Topical treatment 
of mild to moderate acne vulgaris, particularly inﬂ ammatory lesions in adults and adolescents 
from 12 years of age and above. Posology and Method of Administration: Cutaneous use 
only. Adults and Adolescents: Once daily in the evening. Treatment should not exceed more than 
12 weeks. Elderly: No speciﬁ c recommendations. Contraindication: Hypersensitivity to active 
substances, lincomycin and any of the excipients. Precautions for Use: Avoid Contact with the 
mouth, eyes, lips, other mucous membranes or areas of irritated /broken skin. Use with caution 
in patients with a history of regional enteritis, ulcerative colitis and antibiotic-associated colitis. 
If signiﬁ cant diarrhoea occurs or patients suff ers from abdominal cramps, treatment should be 
immediately discontinued. Resistance to clindamycin: Patients with a recent history are more 
likely to have pre-existing anti-microbial resistant Propionibacterium acnes and commmensal 
ﬂ ora. Cross-resistance: May occur when using antibiotic monotherapy. Fertility, Pregnancy and 
Lactation: There is no adequate data. Avoid application of the product to the breast area. Eff ect 
on Ability to Drive or Use Machines: No studies. Side Eff ects: Very Common side eff ects 
(at least 1 in 10) include erythema, peeling and dryness. Common side eff ects (less than 1 in 
10) include burning sensation, photosensitivity and headache. Overdose: No speciﬁ c antidote. 
Treatment should consist of appropriate symptomatic measures or clinically managed. 
Local Presentation: 30g gel. Marketing Authorization Holder: GlaxoSmithKline UK Ltd., 
Trading as Stiefel. Marketing Authorization Number: MA 300/01401. Legal Category: POM.
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The major point made by Marmot in this publication is the 
emphasis he made on issues impacting on health which are well 
beyond what a medical education equips us to deal with, issues with 
are rarely dealt with in medical textbooks or medical journals. 
These factors relate to what he calls ‘the social gradient in health’. 
While there have been great advances in the provision of medical 
facilities, including standards of hospital and medical practice in 
general, there is still quite an enormous variation within any one 
particular country between outcomes for those at the top of the 
social scale compared to those at the bottom. This differential is 
often the effect of social determinants of health which seem to be 
present in all ‘developed’ countries including Malta.
Life expectancy, for instance, is very much socially 
determined and varies significantly within a nation. Marmot 
gives as an example the fact that in the UK, for instance, if 
one takes the underground train (‘Tube’) from Westminster 
in central London, where better-off people are to be found, 
and move eastwards to the deprived areas of East London, life 
expectancy drops a year with every train stop!
Doctors and health practitioners in general deal with 
individuals to the best of their ability. They fix body ailments as 
best they can, and serve also as a repository of knowledge which 
they pass on to their patients and clients. They do not, in general 
feel obliged to delve deeply into the causation of disease, leaving 
this to public health professionals and researchers.
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...if one takes the underground train (‘tube’) froM 
westMinster in central london, where better-off 
people are to be found, and Move eastwards to 
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drops a year with every train stop!
One major cause of ill-health which has not perhaps been 
given sufficient importance, but which now has taken centre 
stage, is the role of social inequality in perpetrating ill health 
amongst the community. There is no doubt that an unequal 
society, that is, one where there is a major differential between 
the well-off and those at the bottom of the social scale, leads 
invariably to a differential between the health of its citizens. 
While the western world is considered to be a rich and healthy 
world, there are invariably sections of the population where 
citizens are hit hard and health is at a nadir. Take for instance the 
US, a country which spends more on health than any other nation 
on earth, there is still a considerable proportion of citizens who 
have a markedly reduced life expectancy, and reduced access to 
health care, compared to much more ‘equal’ societies like Norway 
or Sweden. 
Malta, a small country which is now actually doing well 
economically, one would have thought, qualifies as an equal society, 
with equal access to facilities and little differential between rich and 
poor. However, there is no doubt that here also we find pockets of 
want, and whole families at risk of poverty and ill-health.
The economist Lawrence Zammit claims that while the 
‘middle class’ has increased significantly in size in Malta over 
the past 25 years, in recent years in Malta, we still find that up to 
15.4% are at risk-of-poverty level.5
Moreover, certain localities in Malta are distinctly at a social 
disadvantage compared to the average. One objective yardstick 
is the distribution of social benefits by local area. A recent article 
published in The Times lists localities with the highest number of 
single parents in receipt of children allowance.6 This report states 
that as of 2016 there were nearly 11,000 persons receiving such 
an allowance. St Paul’s Bay and Birkirkara (the most populous 
localities in Malta) were at the top of the list. While females 
constituted the majority of these persons, about one-fifth of these 
single parents were males.
Social issues have been shown to play a very significant part 
in ensuring the creation and perpetuation of health issues. The 
general practitioner in particular, working at the coalface, is often 
considered to be the ideal person to detect the causes of ill-health. 
This option is, however, coming more and more under threat as a 
result of the fluidity of relationships between patient and doctor. 
The one-to-one relationship which used to be de rigueur in the 
past has been eroded, and with it the ability to diagnose familial, 
social, and other background factors which lead to disease in 
certain at-risk individuals and families. 
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Amoxicillin/Clavulanate Potassium
Powder for oral suspension
✓ Provides extended antibacterial 
coverage to include the most penicillin-
resistant strains.1
✓ Recommended by leading Guidelines as 
first line treatment in AOM.2,3
✓ Most common adverse effects are 
diarrhoea, nausea, vomiting and 
mucocutaneous candidiasis.4
✓ Indicated for children <40 kg and 
older than 3 months; dosed at 
90/6.4 mg/kg/day in 2 divided doses.4
Mini Abridged Prescribing Information: Please refer to the full Summary of Product Characteristics (SPC) 
before prescribing. TRADE NAMES: Augmentin ES. ACTIVE INGREDIENTS: Amoxicillin (as trihydrate) 
and potassium clavulanate. PRESENTATIONS: Supplied in 100 ml glass bottle with a dosing spoon. 
INDICATIONS: Treatment of acute otitis media and community acquired pneumonia infections in children 
aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-
resistant Streptococcus pneumoniae. POSOLOGY & ADMINISTRATION: Oral use; recommended dose of 
90/6.4  mg/kg/day in two divided doses. CONTRAINDICATIONS: Hypersensitivity (and past history of) to 
the active substances, to any penicillins or to any of the excipients. SPECIAL WARNINGS & PRECAUTIONS: 
Before initiating therapy careful enquiry of previous hypersensitivity reactions to beta-lactams. Where 
an infection is proven to be due to an amoxicillin susceptible organism, a switch to an amoxicillin-only 
preparation should be considered. Convulsions may occur in patients receiving high doses or who have 
impaired renal function. Concomitant use of allopurinol increase likelihood of allergic skin reactions. 
Prolonged use may occasionally result in overgrowth of non-susceptible organisms. Augmentin ES contains 
aspartame (E951), a source of phenylalanine. The suspension also contains maltodextrin (glucose). Refer 
to the SPC for full list of precautions. INTERACTIONS: Penicillins may reduce the excretion of methotrexate 
causing a potential increase in toxicity. Concomitant use of probenecid is not recommended. If co-
administration with oral anticoagulants is necessary, the prothrombin time or international normalised ratio 
should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the 
dose of oral anticoagulants may be necessary. PREGNANCY & LACTATION: Use should be avoided unless 
considered essential by the physician. UNDESIRABLE EFFECTS: Very common (≥ 1/10): diarrhoea. Common 
(≥ 1/100, < 1/10): mucocutaneous candidosis, nausea, abdominal pain. Refer to the SPC for full list of 
undesirable effects. AUTHORISATION NUMBER: AA 1051/00101. MARKETING AUTHORISATION HOLDER: 
GlaxoSmithKline Bulgaria EOOD. LEGAL CATEGORY: POM. DATE OF PREPARATION: May 2016 In order to 
ensure that this product information reflects the most up-to-date clinical and post-marketing 
surveillance data, please always refer to the latest Summary of Product Characteristics (SPC) 
which is available from GlaxoSmithKline (Malta) Ltd (Tel: +356 21238131) REPORTING ADVERSE 
EVENTS (AEs): If you become aware of any AEs, medication errors and/or use during pregnancy 
in association with GSK products, please report the event promptly to: GSK (Malta) Limited, 1, De 
la Cruz Avenue, Qormi QRM 2458, Malta (Tel: +356 21238131) Alternatively, any suspected AEs and m 
edication errors can also be reported via the national Adverse Drug Reactions (ADRs) reporting 
system: Report forms can be downloaded from www.medicinesauthority.gov.mt/adrportal and posted 
to the Malta Medicines Authority, Post-licensing Directorate, 203, Level 3, Rue D’Argens, Gżira GŻR 1368, 
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